Roflumilast Foam Gets Nod for Seborrheic Dermatitis : vimars

Patients in the roflumilast group showed significant improvements in all secondary endpoints, including itching, scaling, and erythema.

Related Keywords

, Drug Administration , Investigator Global Assessment , Dermatitis , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Seborrheic Dermatitis Seborrhoeic , Pruritus , Pruritis , Pitch , Psoriasis , Hair ,